From the Department of Radiation Oncology, Cyberknife and Radiotherapy, University Hospital Cologne.
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne.
Clin Nucl Med. 2023 Feb 1;48(2):150-155. doi: 10.1097/RLU.0000000000004505.
In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT imaging using [68Ga]-radiolabeled inhibitors of FAP also in cervical cancer (CC). Our study aims to explore the accuracy of [68Ga]Ga-fibroblast activation protein inhibitor (FAPI)-46 PET/CT and [18F]F-FDG PET/CT compared with histopathological results of surgical lymph node (LN) staging before primary chemoradiation.
Seven consecutive women with treatment-naive and biopsy-proven locally advanced CC underwent both whole-body [68Ga]Ga-FAPI-46- and [18F]F-FDG PET/CT, for imaging nodal staging before systematic laparoscopic lymphadenectomy of the pelvic and para-aortic region. Location and number of suspicious LNs in PET imaging were recorded and compared with the results of histopathological analysis, including immunohistochemical staining for FAP.
All 7 patients had focal uptake above background in their tumor lesions in [68Ga]Ga-FAPI-46 PET/CT. [68Ga]Ga-FAPI-46 PET/CT showed a higher tumor-to-background ratio (TBR) in primary tumor as well as in LN metastasis. Median TBRmax values using liver were 32.02 and 5.15 for [68Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT, respectively. Median TBRmax using blood pool was 18.45 versus 6.85 for [68Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT, respectively. Higher TBR also applies for nodal metastasis: TBRmax was 14.55 versus 1.39 (liver) and 7.97 versus 1.8 (blood pool) for [68Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT, respectively. Overall, [68Ga]Ga-FAPI-46 PET/CT detected more lesions compared with [18F]F-FDG PET/CT. Following surgical staging, a total of 5 metastatic LNs could be pathologically confirmed, of which 2 and 4 were positive by [18F]F-FDG PET/CT and [68Ga]Ga-FAPI-46 PET/CT, respectively.
[68Ga]Ga-FAPI-46 PET/CT seems useful to improve detection of nodal metastasis in patients with CCs. Future studies should aim to compare [68Ga]Ga-FAPI-46 PET/CT to surgical staging of pelvic and para-aortic LNs in patients with locally advanced CC.
在几种实体瘤中,肿瘤微环境中的癌相关成纤维细胞过表达成纤维细胞激活蛋白 (FAP)。初步证据表明,使用 [68Ga]-标记的 FAP 抑制剂进行 PET/CT 成像也可在宫颈癌 (CC) 中进行检测和分期。我们的研究旨在探讨 [68Ga]Ga-成纤维细胞激活蛋白抑制剂 (FAPI)-46 PET/CT 和 [18F]F-FDG PET/CT 与原发性放化疗前手术性淋巴结 (LN) 分期的组织病理学结果相比的准确性。
7 名接受过治疗的局部晚期 CC 女性患者均接受全身 [68Ga]Ga-FAPI-46-和 [18F]F-FDG PET/CT 检查,用于在系统性腹腔镜盆腔和腹主动脉旁淋巴结清扫术之前进行淋巴结分期。记录 PET 成像中可疑 LN 的位置和数量,并与包括 FAP 免疫组织化学染色在内的组织病理学分析结果进行比较。
7 名患者的肿瘤病变在 [68Ga]Ga-FAPI-46 PET/CT 中均显示出高于背景的局灶性摄取。[68Ga]Ga-FAPI-46 PET/CT 显示原发性肿瘤和 LN 转移中的肿瘤与背景比 (TBR) 更高。使用肝脏的中位数 TBRmax 值分别为 32.02 和 5.15,用于 [68Ga]Ga-FAPI-46 PET/CT 和 [18F]F-FDG PET/CT。使用血池的中位数 TBRmax 值分别为 18.45 和 6.85,用于 [68Ga]Ga-FAPI-46 PET/CT 和 [18F]F-FDG PET/CT。较高的 TBR 也适用于淋巴结转移:TBRmax 分别为 14.55 和 1.39(肝脏)和 7.97 和 1.8(血池),用于 [68Ga]Ga-FAPI-46 PET/CT 和 [18F]F-FDG PET/CT。总体而言,[68Ga]Ga-FAPI-46 PET/CT 比 [18F]F-FDG PET/CT 检测到更多的病变。在进行手术分期后,共可病理证实 5 个转移性 LN,其中 2 个和 4 个分别通过 [18F]F-FDG PET/CT 和 [68Ga]Ga-FAPI-46 PET/CT 呈阳性。
[68Ga]Ga-FAPI-46 PET/CT 似乎可用于提高宫颈癌患者淋巴结转移的检出率。未来的研究应旨在将 [68Ga]Ga-FAPI-46 PET/CT 与局部晚期 CC 患者的盆腔和腹主动脉旁 LN 手术分期进行比较。